Vertex Pharmaceuticals, Inc. (VRTX) Posts Q1 Loss of 65c/Share; Reports Statistically Significant KALYDECO + VX-661 Ph. 2 Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/13/2026

1. CSCO
2. CBRS
3. COHR
4. WYFI
5. CRS
6. STUB
7. HLIT
8. ABN:NA
9. ABNRY
10. GLNG

Go back to Vertex Pharmaceuticals, Inc. (VRTX) Posts Q1 Loss of 65c/Share; Reports Statistically Significant KALYDECO + VX-661 Ph. 2 Data

Goldman Sachs Comments on Vertex (VRTX)

May 2, 2014 9:39 AM EDT

Goldman Sachs maintained a Neutral rating on Vertex (NASDAQ: VRTX) with a price target of $64.00.

Analyst Terence Flynn said, "In our view 1Q results were uneventful and the focus remains on... More

Vertex (VRTX): H.C. Wainwright Comments on VX-661 Data

May 2, 2014 9:33 AM EDT

H.C. Wainwright maintained a Buy rating on Vertex (NASDAQ: VRTX) with a price target of $105.00. Comments follow data on VX-661.

Analyst Andrew S. Fein said, "Yesterday, VRTX took the final step in its transformation into a CF company by simultaneously eliminating the vestigial VX-135 and by reporting additional positive clinical data on VX-661, which over the course of the last 12... More

Vertex (VRTX) Bullish Stance Reiterated at Needham & Company after Q1 Results, Encouraging VX-661-Ivacaftor Phase 2 Data

May 2, 2014 7:41 AM EDT

Needham & Company analyst Alan Carr reiterated a Buy rating and $95 price target on Vertex (NASDAQ: VRTX) following Q1 results and 'encouraging' VX-661-ivacaftor phase 2 data.

Carr commented, "Vertex reported 1Q14 financial results yesterday and announced positive top-line results from a Phase 2... More